Get startedLog in
    Picture of Quantum Genomics SA logo

    ALQGC — Quantum Genomics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: Quantum Genomics Announces Top-Line Results From Its Phase 2b NEW-HOPE Trial Of Firibastat

    Picture of Quantum Genomics SA logoQuantum Genomics SA
    12/11/2018 06:44
    Nov 12 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * ANNOUNCES EXCELLENT TOPLINE RESULTS FROM PHASE 2B NEW-HOPE
STUDY
EVALUATING FIRIBASTAT FOR ARTERIAL HYPERTENSION
    * THESE RESULTS OPEN THE WAY TO A PIVOTAL PHASE 3 TRIAL WITH
FIRIBASTAT IN RESISTANT HYPERTENSION
    * FIRIBASTAT MEETS PRIMARY ENDPOINT
    * FIRIBASTAT PROVED EFFICACIOUS IN ALL SUBGROUPS
    * FIRIBASTAT WAS CLINICALLY AND BIOLOGICALLY WELL-TOLERATED

Source text for Eikon:  ID:nACT55923 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))

    Recent news on Quantum Genomics SA

    See all news